ReviewStem cell reviews and reports2021
Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19.
Review in Stem cell reviews and reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Stem Cells as a Model of Study of SARS-CoV-2 and COVID-19: A Systematic Review of the Literature.BioMed research international · 2021Pooled it
- Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.Stem cell research & therapy · 2023Trial
- Identification of Gene Signatures Associated with COVID-19 across Children, Adolescents, and Adults in the Nasopharynx and Peripheral Blood by Using a Machine Learning Approach.Current gene therapy · 2025Article
- hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway.Molecular biomedicine · 2023Article
- Stromal cell therapy in cats with feline chronic gingivostomatitis: current perspectives and future direction.Journal of feline medicine and surgery · 2023Review
- Tendon-Derived Mesenchymal Stem Cells (TDSCs) as an In Vitro Model for Virological Studies in Wild Birds.Viruses · 2023Article
- Stem cell therapy: a novel approach against emerging and re-emerging viral infections with special reference to SARS-CoV-2.Molecular biology reports · 2023Review
- Mechanism of Mesenchymal Stem Cells as a Multitarget Disease- Modifying Therapy for Parkinson's Disease.Current neuropharmacology · 2023Review
- Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.Stem cell research & therapy · 2022Review
- Stem cell therapy for COVID-19 pneumonia.Molecular biomedicine · 2022Review
- Reactive Oxygen Species in the Adverse Outcome Pathway Framework: Toward Creation of Harmonized Consensus Key Events.Frontiers in toxicology · 2022Review
- Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.Regenerative engineering and translational medicine · 2022Review
- Review
- Translating extracellular vesicle packaging into therapeutic applications.Frontiers in immunology · 2022Review
- Aqueous extract ofJournal of stem cells & regenerative medicine · 2022Article
- Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2.Pathogens (Basel, Switzerland) · 2021Review
- Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era.Stem cell research & therapy · 2021Review
- Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Based Treatment of Viral Diseases.Pathogens (Basel, Switzerland) · 2021Review
- Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.Stem cell reviews and reports · 2021Review
- Microencapsulated Wharton Jelly-derived adult mesenchymal stem cells as a potential new therapeutic tool for patients with COVID-19 disease: an in vitro study.American journal of stem cells · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells with immunomodulatory and regenerative properties that support their therapeutic use. MSCs isolated from many tissue sources replicate vigorously in vitro and maintain their main biological properties allowing their widespread clinical application. To date, most MSC-based preclinical and clinical trials targeted immune-mediated and inflammatory diseases. Nevertheless, MSCs have antiviral properties and have been used in the treatment of various viral infections in the last years. Here, we revised in detail the biological properties of MSCs and their preclinical and clinical applications in viral diseases, including the disease caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (COVID-19). Notably, rapidly increasing numbers of MSC-based therapies for COVID-19 have recently been reported. MSCs are theoretically capable of reducing inflammation and promote lung regeneration in severe COVID-19 patients. We critically discuss the rationale, advantages and disadvantages of MSC-based therapies for viral infections and also specifically for COVID-19 and point out some directions in this field. Finally, we argue that MSC-based therapy may be a promising therapeutic strategy for severe COVID-19 and other emergent respiratory tract viral infections, beyond the viral infection diseases in which MSCs have already been clinically applied. Graphical Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.